Ardelyx (ARDX) Cash from Investing Activities (2013 - 2026)
Ardelyx (ARDX) reported Cash from Investing Activities of -$10.0 million for Q1 2026, down 450.58% on a YoY basis from $2.9 million in Q1 2025, and down 364.7% quarter-over-quarter from $3.8 million in Q4 2025.
Ardelyx (ARDX) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Ardelyx has reported Cash from Investing Activities for 14 years, with the latest figure at -$10.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 450.58% year-over-year to -$10.0 million; the trailing twelve-month figure through Mar 2026 stood at -$21.8 million (down 69.1% YoY), and the FY2025 full-year result was -$9.0 million, up 51.09% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$10.0 million, down from $3.8 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $34.9 million in Q2 2025, with the low at -$59.2 million in Q2 2023.
- Historically, Cash from Investing Activities has averaged -$8.8 million across 5 years, with a median of -$832000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities tumbled 3829.93% — and 2025, when it jumped 210.85%.
- Ardelyx's Cash from Investing Activities stood at $1.4 million in 2022, then slumped by 2151.84% to -$29.6 million in 2023, then sank by 40.77% to -$41.6 million in 2024, then surged by 109.07% to $3.8 million in 2025, then slumped by 364.7% to -$10.0 million in 2026.
- The last three Cash from Investing Activities figures came in at -$10.0 million (Q1 2026), $3.8 million (Q4 2025), and -$50.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | -10.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.00 Mn |
| Mar 31, 2026 | -10.00 Mn |
| Dec 31, 2025 | 3.78 Mn |
| Dec 31, 2025 | 3.78 Mn |
| Sep 30, 2025 | -50.51 Mn |
| Sep 30, 2025 | -50.51 Mn |
| Jun 30, 2025 | 34.92 Mn |
| Jun 30, 2025 | 34.92 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Dec 31, 2024 | -41.62 Mn |
| Dec 31, 2024 | -41.62 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 23.53 Mn |
| Jun 30, 2024 | 23.53 Mn |
| Mar 31, 2024 | -2.57 Mn |
| Mar 31, 2024 | -2.57 Mn |
| Dec 31, 2023 | -29.57 Mn |
| Dec 31, 2023 | -29.57 Mn |